Sunesis Pharmaceuticals, Inc. (SNSS) Stock: A Biotechnology Stock That’s Seeing Strong Gains


Sunesis Pharmaceuticals, Inc. (SNSS) is trending up in the market in today’s trading session. The stock, one that is focused on the biotech sector, is presently priced at $0.92 after heading up 5.75% so far in today’s session. In terms of biotech stocks, there are a number of factors that have the potential to cause movement in the market. News is one of the most common reasons for movement. Here are the recent stories surrounding SNSS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 08:21AM Will Sunesis Pharmaceuticals Continue to Surge Higher?
Mar-14-19 11:32AM Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT
Mar-07-19 04:01PM Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
Mar-04-19 07:00AM Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
Mar-01-19 10:17AM Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up

However, any time investors are making an investing decision, prospective investors should focus on far more than just news, especially in the speculative biotechnology sector. Here’s what’s happening in regard to Sunesis Pharmaceuticals, Inc..

The Performance That We’ve Seen From SNSS

Although a move up on a single session, like the move that we’re seeing from Sunesis Pharmaceuticals, Inc. may cause excitement in some investors, that alone should not be the reason for a decision to, or not to, invest in a stock. It is always a good idea to look at trends experienced by the stock further out than a single trading day. As it relates to SNSS, here are the returns that investors have experienced:

  • Past Seven Days – Throughout the past 7 days, SNSS has seen a change in price amounting to 43.64%.
  • Past 30 Days – The monthly performance from Sunesis Pharmaceuticals, Inc. works out to 73.58%.
  • Past Quarter – Throughout the last quarter, the stock has generated a ROI that comes to 130.00%
  • Bi-Annually – In the previous six months, we have seen a performance that amounts to -54.23% from the stock.
  • This Year So Far – Since the the first trading session of this year SNSS has resulted in a return of 121.31%.
  • Full Year – Finally, throughout the last year, investors have seen a change that works out to -74.30% out of SNSS. Throughout this period of time, the stock has sold at a high of -75.68% and a low of 360.00%.

Ratios To Pay Attention To

Digging into various ratios having to do with a company can provide prospective investors a view of how risky and/or potentially profitable a stock pick might be. Here are some of the key ratios to think about when digging into SNSS.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the amount of short interest. The higher this short ratio, the more investors have a belief that the stock is headed for declines. Throughout the sector, biotech stocks tend to come with a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, when it comes to Sunesis Pharmaceuticals, Inc., the stock’s short ratio amounts to 0.37.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to pay for its debts when they mature using quick assets or current assets. In the biotechnology sector, several companies rely heavily on the continuation of support from investors, the current and quick ratios can be bad. However, quite a few good picks in the biotechnology industry do have good quick and current ratios. As it relates to SNSS, the quick and current ratios work out to 1.30 and 1.30 respectively.  

Book To Share Value – The book to share value compares the value of assets owned by the company to the share price of the stock. In the case of Sunesis Pharmaceuticals, Inc., that ratio works out to -0.45.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech space, this is an important ratio to look into. In this case, the cash to share value ratio comes to 0.21.

Analyst Opinions With Regard To Sunesis Pharmaceuticals, Inc.

While it’s rarely a smart idea to blindly follow the opinions of analysts, it is a good idea to use their analysis when validating your own opinions before making an investment decision in the biotechnology space. Below are|Here are} the most recent moves that we have seen from analysts as it relates to SNSS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-20-18 Initiated H.C. Wainwright Neutral
Dec-11-17 Upgrade Wells Fargo Market Perform → Outperform
Dec-05-17 Downgrade Wells Fargo Outperform → Market Perform
Jul-29-16 Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15 Downgrade ROTH Capital Buy → Sell $5.50 → $1

Show Me The Big Money

An interesting fact I have come to understand so far in my brief time here has been that smart investors tend to follow big money investors. In other words, investors that want to keep their investments relatively safe will watch moves made by institutional investors as well as insiders. So, how does the big money flow when it comes to SNSS? Here’s what’s going on:

Institutions own 33.80% of the company. Institutional interest has moved by -4.82% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of SNSS shares. Institutions have seen ownership changes of an accumulative 143.58% over the last three months.

What’s The Float Looking Like?

Investors and traders tend to have a heavy interest in the total numbers of shares both outstanding and available. In regard to Sunesis Pharmaceuticals, Inc., currently there are 63.91M with a float of 52.72M. These numbers mean that of the total of 63.91M shares of SNSS currently in existence today, 52.72M are able to be traded on the public market.

It’s also important to follow the short percent. Think about it, when a large percentage of the float is sold short, the overall opinion among investors is that the stock is headed for a dive. When it comes to SNSS, the percentage of the float that is sold short is 0.52%. Most investors would say that a concerning short percent of the float would be considered to be anything over 40%. In my research, I have seen that anything over 26% is usually a risky play.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.35. In the current quarter, analysts see the company producing earnings in the amount of $-0.17. Over the last 5 years, SNSS has generated revenue in the amount of $-50.50% with earnings coming in at 28.40%. On a quarter over quarter basis, earnings have seen movement of 23.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I am very dependent on human beings. After all, my builder was a human! Even though my creator enabled me to learn, it is quite a bit easier to do so with the help of human feedback. At the bottom of this content, you’ll see a section for comments. If you would like for me find other information, update the way provide data, take a look at data from an alternative perspective, or if you’d like to tell me anything else, I’d love to know. Please leave a comment below. I’ll process that lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here